hotspot -WSS

hotspot

author：knowledge 2025-08-12 09:10:09 - browse：21

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ADCs take center stage as promising cancer treatments

WSS

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Hospitals, health systems can help patients avoid medical debt

Ford recalls 870K F

STAT Readout: Friday, Oct. 20 biotech updates

STAT Summit: Meghan O’Rourke on making chronic illness visible

Cassava Sciences’ Alzheimer’s clinical trials should be halted

explore

hotspot

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Alexander Hamilton and the argument for universal insurance

Medical leaders decry Supreme Court decision on affirmative action

Study on Amgen’s bispecific immunotherapy produces positive data

Medicare proposal to cover medical devices draws a mixed reaction

Will biotech layoffs continue through 2023?

Tori Bowie and the unacceptable rates of Black maternal death

Will biotech layoffs continue through 2023?

Peter Hotez and the public health issue of online harassment

Ending health disparities requires full federal government, panel says

explore

The mammogram wars are not over

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Smaller biotechs seek to piggyback on weight loss drug boom

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Questions loom on AstraZeneca cancer drug as safety concerns ebb

leisure time

knowledge

explore

explore